Clovis Oncology Competitors, Revenue and Alternatives

Claim your profile

Overview

Location:
Boulder, CO USA
Total Funding:$763.3M
Industry:Biotech
Founded:2009
Lead Investor(s):J. P. Morgan Securities LLC, BofA Merrill Lynch
Press
Claim your profile

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Clovis Oncology's estimated annual revenue is currently $95.4M per year.
  • Clovis Oncology received $445.0M in venture funding in April 2018.
  • Clovis Oncology's estimated revenue per employee is $182,736
  • Clovis Oncology's total funding is $763.3M.

Employee Data

  • Clovis Oncology has 522 Employees.
  • Clovis Oncology grew their employee count by -1% last year.
  • Clovis Oncology currently has 15 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
CereScan
$4.5M29N/AN/A
ARCA biopharma
N/A22N/AN/A
Flagship Biosci...
$6.7M43N/AN/A
Mile High Labs
$14.3M92-50%N/A
GlobeImmune
$5.6M360%N/A
Strand Life Sci...
$57M368N/AN/A
Isolate Extract...
$8.4M5435%N/A
Biodesix
$23.9M1541%N/A
Cerecin, previo...
N/A36N/AN/A
Horizon Ag-Prod...
$8.7M56N/AN/A
Missing a competitor? Contribute!?
Submit

We are a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. We target our development programs for the treatment of specific subsets of cancer populations, and simultaneously develop, with partners, companion diagnostics intended to direct a compound in development to the population that is most likely to benefit from its use. Our first commercial product and lead product candidate, Rubraca® (rucaparib) tablets, is an oral, small molecule poly ADP-ribose polymerase, or PARP, inhibitor of PARP1, PARP2 and PARP3. Studies open for enrollment or under consideration include ovarian, prostate, breast, gastroesophageal, pancreatic, lung and bladder cancers. Clovis holds worldwide rights for Rubraca. In the United States, Rubraca is approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Rubraca is also approved in the United States for the treatment of adult patients with deleterious BRCA mutation (germline and/or somatic) associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. Rubraca is an unlicensed medical product outside of the U.S. In addition, we have two other product candidates: lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors (VEGFR) 1-3, platelet-derived growth factor receptors (PDGFR) alpha and beta and fibroblast growth factor receptors (FGFR) 1-3, and rociletinib, an oral mutant-selective inhibitor of epidermal growth factor receptor (EGFR). We maintain certain development and commercialization rights for lucitanib and global development and commercialization rights for rociletinib.

keywords:Biotechnology,Healthcare,Pharmaceuticals

522

Number of Employees

$95.4M

Revenue (est)

15

Current Jobs

-1%

Employee Growth %

$763.3M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Executive Contacts

NameTitleEmail
Pat MahaffyChief Executive Officer, President & DirectorEmail Available
Thomas HardingChief Scientific OfficerEmail Available
Gillian Ivers-ReadEvp Regulatory Affairs &tech.opsEmail Available
John BullardDirector National AccountsEmail Available
Kent JohnsTerritory Sales Manager
Michael FairchildRegional Sales Director - WestEmail Available
Nishit AgrawalAssociate DirectorEmail Available
Aaron EnkeDirector, Clinical ScienceEmail Available
Chuck BradburyVice President, Accounting & TreasuryEmail Available
Kate PetersenProduct Marketing ManagerEmail Available

Clovis Oncology News

09/03/2019 - Near an All-Time Low, Is Clovis Oncology a Buy?

The collapse of Clovis Oncology (NASDAQ: CLVS) stock has been stunning. Shares were trading at over $75 apiece in the middle of 2017, and ...

09/08/2019 - 48,598 Shares in Clovis Oncology (NASDAQ:CLVS) Purchased by First Trust Advisors LP

First Trust Advisors LP purchased a new position in shares of Clovis Oncology (NASDAQ:CLVS) during the 2nd quarter, according to its most ...

09/03/2019 - Scrutiny of these stocks:: Clovis Oncology, Inc., (NASDAQ: CLVS)

Each buying and selling session display one-of-a-kind actions and patterns about Clovis Oncology, Inc. CLVS), Biotechnology stock. Presently ...

Clovis Oncology Funding

DateAmountRoundLead InvestorsReference
2015-07-13$UndisclosedUndisclosedJ. P. Morgan Securities LLCArticle
2017-01-04$175.0MUndisclosedJ. P. Morgan Securities LLCArticle
2017-06-21$250.0MUndisclosedJ. P. Morgan Securities LLCArticle
2018-04-17$445.0MUndisclosedJ. P. Morgan Securities LLCArticle

Clovis Oncology Executive Hires

DateNameTitleReference
2016-01-26Dale HooksSVP/Chief Commercial OfficerArticle